(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Tuesday, October 28, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE² Registry and Medicare Fee-For-Service Claims Data
Abstract Poster Presenter: Julia Buchfuhrer, DO – JB Arthritis and Rheumatology Center
10:30 AM - 12:30 PM Central Time

Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
10:30 AM - 12:30 PM Central Time

Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
10:30 AM - 12:30 PM Central Time

Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
10:30 AM - 12:30 PM Central Time

Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
Abstract Poster Presenter: Patrick Williamson, MD (he/him/his) – UAB Internal Medicine Residency
10:30 AM - 12:30 PM Central Time

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
10:30 AM - 12:30 PM Central Time

Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Abstract Poster Presenter: Min Jung Kim, MD – Seoul Metropolitan Government Boramae Medical center
10:30 AM - 12:30 PM Central Time

Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Abstract Poster Presenter: Tony Merriman, PhD – University of Alabama at Birmingham
10:30 AM - 12:30 PM Central Time

Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
Abstract Poster Presenter: Kanon Jatuworapruk, MD – Thammasat University
10:30 AM - 12:30 PM Central Time

Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
10:30 AM - 12:30 PM Central Time

Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Abstract Poster Presenter: Alex Tinianow, MD – Vanderbilt University Medical Center
10:30 AM - 12:30 PM Central Time

Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
10:30 AM - 12:30 PM Central Time

Bone health in patients with gout using real-world U.S. data
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
10:30 AM - 12:30 PM Central Time

The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Abstract Poster Presenter: Chio Yokose, MD, MSc (she/her/hers) – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
10:30 AM - 12:30 PM Central Time

Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
Abstract Poster Presenter: Cristina Rodríguez Alvear, III, -None- – Hospital Doctor José Molina Orosa
10:30 AM - 12:30 PM Central Time

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m²:A Post-Hoc Analysis of 24-Week Data
Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
10:30 AM - 12:30 PM Central Time

Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
Abstract Poster Presenter: Janis Timsans, MD – Päijät-Häme Central Hospital, Department of Rheumatology
10:30 AM - 12:30 PM Central Time

Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Abstract Poster Presenter: Bradley Marder, MD – AMGEN, Inc
10:30 AM - 12:30 PM Central Time

Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
Abstract Poster Presenter: Lesley Jackson, MD, MSPH – University of Alabama at Birmingham
10:30 AM - 12:30 PM Central Time

Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Abstract Poster Presenter: Jason Yang, MD, PhD (he/him/his) – Boston Medical Center
10:30 AM - 12:30 PM Central Time

Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Abstract Poster Presenter: Natalie McCormick, PhD – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

A Phase 1 Placebo Controlled, Single (SAD) and Multiple Dose Escalation (MAD) Safety and Pharmacokinetic (PK) Study of a Novel Colchicine Analogue ABP-745 in Healthy Volunteers (HV)
Abstract Poster Presenter: Ullrich Schwertschlag, MD, PhD (he/him/his) – Atom Therapeutics
10:30 AM - 12:30 PM Central Time

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
Abstract Poster Presenter: Ullrich Schwertschlag, MD, PhD (he/him/his) – Atom Therapeutics
10:30 AM - 12:30 PM Central Time

Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Abstract Poster Presenter: Joshua Baker, MD, MS – University of Pennsylvania